Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus sitagliptin MRI renal filtration study in type 2 diabetes
ACTRN12619000933156Phase 4Completed
- Sponsor
- Austin Health
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Austin Health. Primary endpoint: Primary: change in MRI-derived glomerular filtration rate. Started May 2017; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12619000933156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000933156.